- Conditions
- Dravet Syndrome
- Interventions
- Clobazam, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 1 Year to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 1,792
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glabellar Lines
- Interventions
- MT10109L, Placebo
- Drug
- Lead sponsor
- Medy-Tox
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 6 more
- Conditions
- Opioid-Related Disorders
- Interventions
- Lofexidine, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Depressive Symptoms
- Interventions
- Freeze-dried Blueberry Powder, Placebo Powder
- Other
- Lead sponsor
- Hebrew SeniorLife
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Roslindale, Massachusetts
- Conditions
- Collagen Synthesis
- Interventions
- Epicatechin-rich cocoa dose response, Epicatechin-rich cocoa vs placebo on performance
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 25 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Schizo-Affective Type of Psychosis, Schizophrenia
- Interventions
- Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
- Behavioral · Diagnostic Test · Biological
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Renal Colic
- Interventions
- Lidocaine, Ketorolac
- Drug
- Lead sponsor
- The Brooklyn Hospital Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Mild Traumatic Brain Injury, Photophobia
- Interventions
- Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psychomotor Impairment
- Interventions
- Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
- Drug
- Lead sponsor
- Marion Coe
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Trigeminal Neuralgia
- Interventions
- lamotrigine, Placebo
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-melanoma Skin Cancer
- Interventions
- topical diclofenac daily, placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ketosis
- Interventions
- Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis
- Dietary Supplement · Behavioral · Biological + 2 more
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 20 Years to 30 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration
- Drug · Procedure · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 41
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
- Radiation · Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more
- Conditions
- Fear
- Interventions
- NeuroConn Direct Current stimulator Multiple Channel -4
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Obesity, Binge Eating
- Interventions
- Xenical + behavioral intervention, Behavioral intervention + placebo
- Drug · Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
- Interventions
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
- Procedure · Drug · Biological
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Asthma, Acute Asthma, Reactive Airway Exacerbation
- Interventions
- Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
- Interventions
- VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification
- Drug · Behavioral
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Norman, Oklahoma
- Conditions
- Obesity
- Interventions
- Auricular Acupuncture, Sham Acupuncture
- Other
- Lead sponsor
- Mike O'Callaghan Military Hospital
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Parkinson Disease, Falls Patient
- Interventions
- Droxidopa, Placebo
- Drug · Other
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 30 Years to 83 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Autism, Autism Spectrum Disorder
- Interventions
- Epidiolex, placebo oral solution
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 7 Years to 14 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- COVID-19
- Interventions
- BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Interventions
- Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet
- Drug
- Lead sponsor
- Alicia Gerke
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa